EMA adopts positive scientific opinion on our ivermectin/albendazole fixed-dose coformulation
The STOP2030 Consortium is pleased to announce that the Committee [...]
STOP2030 team at InCORNTD 2025
Colleagues from the STOP2030 consortium attended last week the [...]
Our FDC of albendazole & ivermectin demonstrates safety and superior efficacy in phase 2-3 trial
Researchers from African, Latin American and European organisations have published [...]
WHO Publishes the First Guidelines for Controlling Strongyloides stercoralis
Controlling Strongyloides stercoralis: WHO's recommendations for addressing it as a [...]
Our latest popPK study supports the dosing strategy of our ivermectin/albendazole FDC
A new paper on the population pharmacokinetics (PK) of our [...]
ESACIPAC (KEMRI) designated as a WHO Collaborating Centre on NTDs
The Eastern and Southern Africa Centre of International Parasite [...]
Innovating a 50-Year-Old Drug: The Fixed-Dose Ivermectin Approach
The quest to find optimal treatment strategies for Neglected [...]
STOP2030 Consortium Gathers in Nairobi to Plan Steps Towards the Finish Line
On June 5-6, the seven partner organizations within the STOP2030 [...]
Collins Okoyo earned his PhD by modelling the best strategies for the elimination of STH
We are happy to announce that Collins Okoyo, the STOP2030’s [...]
STOP2030 welcomes its Scientific & Technical Advisory Board
Our project has taken an important step forward by [...]
